Active Leukemia Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

Why Consider a Leukemia Clinical Trial?

• Find Trials That Fit — Browse recruiting Leukemia trials pulled directly from ClinicalTrials.gov — updated continuously so you always see real, active studies.
• No Medical Jargon — Eligibility criteria are rewritten into plain yes-or-no questions. It's always okay to answer "not sure" — your doctor can help fill in the rest.
• See How Well You Match — Get a clear picture of how closely a trial fits your situation, so you know which ones are worth bringing to your oncologist.
• Ready for Your Appointment — Generate a printable or emailable summary for your next visit. A caregiver can send it to your doctor ahead of time.

How It Works

1. Share a Few Details — Enter your Leukemia type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Leukemia Clinical Trial FAQ

Are leukemia clinical trials different for AML, ALL, CLL, and CML?

Yes — AML, ALL, CLL, and CML are biologically distinct diseases with separate trial landscapes. AML trials often focus on FLT3, IDH1/2, and BCL-2 inhibitors. ALL trials study CAR-T therapies, bispecific antibodies (blinatumomab), and novel chemotherapy combinations. CLL trials test BTK inhibitors and BCL-2 inhibitors. CML trials evaluate next-generation BCR-ABL inhibitors. Trialify helps you filter by leukemia type.

Can I join a leukemia trial if I am elderly or have other health conditions?

Many leukemia trials now include older or less-fit patients because the disease itself disproportionately affects this population. Trials specifically designed for older adults or patients ineligible for intensive chemotherapy are available for AML and CLL. Your performance status (ECOG) and organ function tests (kidney, liver) are the main factors that determine eligibility.

Do leukemia trials require a stem cell transplant?

Not all leukemia trials involve transplant, but some test new conditioning regimens or graft-versus-host disease (GVHD) prevention strategies around transplant. Other trials are specifically for patients who relapsed after transplant. Many trials are purely drug-based and do not involve transplant at all.

What genetic mutations matter for leukemia trial eligibility?

Molecular profiling is critical in leukemia. Key mutations include FLT3, IDH1, IDH2, NPM1, and TP53 in AML; Philadelphia chromosome (BCR-ABL) status in ALL and CML; and IGHV mutation status, TP53, and 17p deletion in CLL. These mutations determine which targeted therapies are appropriate and which trials you qualify for.

How do I know if a leukemia trial is the right option for me right now?

The right time to consider a trial varies by leukemia type and stage. For newly diagnosed leukemia, some trials are first-line treatments. For relapsed disease, trials may offer access to therapies not yet commercially available. Trialify can help you identify options quickly so you and your oncologist can make an informed decision.

Explore Other Cancer Trial Guides

• Acute Myeloid Leukemia (AML) — Acute myeloid leukemia (AML) is a rapidly progressing blood cancer with several molecularly defined subtypes. Targeted therapies (FLT3, IDH1/2, BCL-2 inhibitors), novel immunotherapy, and CAR-T are being tested in trials for newly diagnosed, elderly-unfit, and relapsed/refractory AML.
• Lymphoma — Lymphoma trials are studying CAR-T cell therapies, bispecific antibodies, and targeted agents for both Hodgkin and non-Hodgkin subtypes — including diffuse large B-cell, follicular, and mantle cell lymphoma.
• Multiple Myeloma — Multiple myeloma trials are advancing CAR-T therapies, bispecific antibodies, BCMA-targeted agents, and novel triplet combinations — offering new paths for newly diagnosed and relapsed/refractory patients.
• Brain Cancer — Brain cancer trials are testing IDH inhibitors, tumor-treating fields (TTFields), CAR-T therapies, and oncolytic viruses — with studies available for glioblastoma, grade 2/3 glioma, and brain metastases.